Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

441 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Antiretroviral Therapy Reduces T-cell Activation and Immune Exhaustion Markers in Human Immunodeficiency Virus Controllers.
Li JZ, Segal FP, Bosch RJ, Lalama CM, Roberts-Toler C, Delagreverie H, Getz R, Garcia-Broncano P, Kinslow J, Tressler R, Van Dam CN, Keefer M, Carrington M, Lichterfeld M, Kuritzkes D, Yu XG, Landay A, Sax PE; AIDS Clinical Trials Group Study A5308 Team. Li JZ, et al. Among authors: kuritzkes d. Clin Infect Dis. 2020 Apr 10;70(8):1636-1642. doi: 10.1093/cid/ciz442. Clin Infect Dis. 2020. PMID: 31131858 Free PMC article. Clinical Trial.
Prevalence and clinical significance of zidovudine resistance mutations in human immunodeficiency virus isolated from patients after long-term zidovudine treatment. AIDS Clinical Trials Group 116B/117 Study Team and the Virology Committee Resistance Working Group.
Japour AJ, Welles S, D'Aquila RT, Johnson VA, Richman DD, Coombs RW, Reichelderfer PS, Kahn JO, Crumpacker CS, Kuritzkes DR. Japour AJ, et al. Among authors: d aquila rt, kuritzkes dr. J Infect Dis. 1995 May;171(5):1172-9. doi: 10.1093/infdis/171.5.1172. J Infect Dis. 1995. PMID: 7538548
Prognostic value of plasma human immunodeficiency virus type 1 (HIV-1) RNA levels in patients with advanced HIV-1 disease and with little or no prior zidovudine therapy. AIDS Clinical Trials Group Protocol 116A/116B/117 Team.
Welles SL, Jackson JB, Yen-Lieberman B, Demeter L, Japour AJ, Smeaton LM, Johnson VA, Kuritzkes DR, D'Aquila RT, Reichelderfer PA, Richman DD, Reichman R, Fischl M, Dolin R, Coombs RW, Kahn JO, McLaren C, Todd J, Kwok S, Crumpacker CS. Welles SL, et al. Among authors: d aquila rt, kuritzkes dr. J Infect Dis. 1996 Oct;174(4):696-703. doi: 10.1093/infdis/174.4.696. J Infect Dis. 1996. PMID: 8843205
Monitoring plasma HIV-1 RNA levels in addition to CD4+ lymphocyte count improves assessment of antiretroviral therapeutic response. ACTG 241 Protocol Virology Substudy Team.
Hughes MD, Johnson VA, Hirsch MS, Bremer JW, Elbeik T, Erice A, Kuritzkes DR, Scott WA, Spector SA, Basgoz N, Fischl MA, D'Aquila RT. Hughes MD, et al. Among authors: d aquila rt, kuritzkes dr. Ann Intern Med. 1997 Jun 15;126(12):929-38. doi: 10.7326/0003-4819-126-12-199706150-00001. Ann Intern Med. 1997. PMID: 9182469 Clinical Trial.
In vivo analysis of Fas/FasL interactions in HIV-infected patients.
Badley AD, Dockrell DH, Algeciras A, Ziesmer S, Landay A, Lederman MM, Connick E, Kessler H, Kuritzkes D, Lynch DH, Roche P, Yagita H, Paya CV. Badley AD, et al. Among authors: kuritzkes d. J Clin Invest. 1998 Jul 1;102(1):79-87. doi: 10.1172/JCI2691. J Clin Invest. 1998. PMID: 9649560 Free PMC article.
Immunologic responses associated with 12 weeks of combination antiretroviral therapy consisting of zidovudine, lamivudine, and ritonavir: results of AIDS Clinical Trials Group Protocol 315.
Lederman MM, Connick E, Landay A, Kuritzkes DR, Spritzler J, St Clair M, Kotzin BL, Fox L, Chiozzi MH, Leonard JM, Rousseau F, Wade M, Roe JD, Martinez A, Kessler H. Lederman MM, et al. Among authors: kuritzkes dr. J Infect Dis. 1998 Jul;178(1):70-9. doi: 10.1086/515591. J Infect Dis. 1998. PMID: 9652425 Clinical Trial.
Characterization of viral dynamics in human immunodeficiency virus type 1-infected patients treated with combination antiretroviral therapy: relationships to host factors, cellular restoration, and virologic end points.
Wu H, Kuritzkes DR, McClernon DR, Kessler H, Connick E, Landay A, Spear G, Heath-Chiozzi M, Rousseau F, Fox L, Spritzler J, Leonard JM, Lederman MM. Wu H, et al. Among authors: kuritzkes dr. J Infect Dis. 1999 Apr;179(4):799-807. doi: 10.1086/314670. J Infect Dis. 1999. PMID: 10068574
441 results